The purity figure
and the paper behind it.

LIPO-C

This is a 326mg Multi-Component Lipotropic Research Reagent designed strictly for laboratory investigation of hepatic lipid metabolism, mitochondrial fatty-acid oxidation pathways, and transmethylation biochemistry. It features a lyophilized blend of five scientifically characterized components - L-Carnitine (200mg), L-Methionine (25mg), Myo-Inositol (50mg), Choline Chloride (50mg), and Cyanocobalamin (1mg)  each targeting a distinct metabolic research endpoint. This formulation enables researchers to investigate simultaneous multi-pathway lipotropic effects in a single, standardized reagent batch. Not for consumption, parenteral administration, or any application outside a controlled laboratory setting.

10ml

Cagri

Cagri (AM-833; CAS 1393461-38-5) is a synthetic, lipidated long-acting analogue of the pancreatic peptide hormone amylin, engineered for sustained activity at all three amylin receptor subtypes (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR) — classifying it as a dual amylin and calcitonin receptor agonist (DACRA). A C20 fatty diacid N-terminal lipidation strategy enables albumin binding, reducing plasma clearance and extending circulating half-life to approximately 159–195 hours (~7 days) in pharmacokinetic research studies. Targeted structural modifications (14E/17R salt-bridge substitutions; 25P/28P/29P proline substitutions) simultaneously prevent amyloid fibril formation. Cryo-EM structures published in Nature Communications (2025) resolve Cagri bound to Gs-coupled active AMY1R, AMY2R, AMY3R, and CTR at atomic resolution. Preclinical research in RAMP1/3 knockout mouse models confirms that Cagri's metabolic signalling effects are specifically dependent on intact AMY1R and AMY3R function in hindbrain neuronal circuits (area postrema/NTS). FOR RESEARCH USE ONLY. Not for consumption, human or animal administration, or any application outside a controlled non-clinical laboratory setting.

NAD+

NAD+ Boosting Compounds combine Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR) with specially designed peptide modulators to create a reliable research model for studying cellular energy and mitochondrial function. This formulation supports laboratory research focused on NAD+ biosynthesis, ATP production, and oxidative balance — key pathways behind energy regulation and cellular repair. The combination enhances molecular stability, uptake efficiency, and experimental reproducibility, making it ideal for achieving consistent results in biochemical studies. LYOPHILIZED POWDER - Requires Reconstitution

SKU NAD-500MG-7142

GLP-1-S

GLP-1-S is a long-acting GLP-1 receptor agonist derived from human GLP-1 and engineered for extended activity through DPP-4 resistance and albumin binding. Registered as PubChem CID 56843331 (C187H291N45O59; 4113.58 g/mol), it is the active pharmaceutical ingredient in Ozempic, Wegovy, and Rybelsus. This scientific reference resource provides molecular, pharmacological, and 2026 regulatory overview information for academic and professional use.

GLP/GIP/GLC-Rt

GLP/GIP/GLC-Rt Research Grade (RUO) (CAS 2381089-83-2, LY3437943) is a 39–amino acid unimolecular peptide designed as a triple agonist for GIP / GLP-1 / Glucagon (GCG) receptors. Supplied as a lyophilized white powder with ≥99% purity (HPLC verified) and endotoxin <1.0 EU/mg, it is soluble in Solution. The molecule includes a C20 fatty diacid moiety for albumin binding and extended stability (reported ~6-day half-life), supporting metabolic, obesity, T2D, and hepatic defatting research models.For Research Use Only (RUO). Not for human or veterinary use.

Survo

Survo (BI 456906; CAS 2805997-46-8; PubChem CID 168429725) is a synthetic, acylated 29-amino-acid research peptide derived from the glucagon backbone, engineered as a dual agonist at glucagon receptors (GCGR) and GLP-1 receptors (GLP-1R). A C18 fatty diacid side chain at position 24, linked via a hydrophilic glycine-serine spacer, enables albumin binding for extended circulating presence and once-weekly research protocol administration. A non-coded amino acid (1-aminocyclobutane-1-carboxylic acid; Ac4c) at position 2 differentiates Survo from native glucagon and enhances receptor selectivity. Developed by Boehringer Ingelheim under licence from Zealand Pharma, Survo is in Phase 3 clinical research programmes (SYNCHRONIZE series for body-weight management; LIVERAGE programme for MASH) and holds FDA Breakthrough Therapy Designation for non-cirrhotic MASH with moderate to advanced fibrosis. It is not approved by the FDA for any indication as of March 2026. FOR RESEARCH USE ONLY. Not for consumption, human or animal administration, or any application outside a controlled non-clinical laboratory setting. Researchers require institutional approval, appropriate biosafety protocols, and batch COA documentation before any laboratory use.

Reconstitution Solution

This Reconstitution Solution is a sterile, non-pyrogenic aqueous diluent containing 0.9% (9 mg/mL) benzyl alcohol as an antimicrobial preservative. Designed strictly for controlled laboratory workflows, the preservative inhibits microbial growth, allowing researchers to make repeated volume transfers from a single multi-draw container over 28 days. It is supplied as a research-grade reference diluent for precise reagent reconstitution. Not for human or animal use, or any application outside a controlled laboratory setting.

GLP/GIP-Tz

This is a Research Reagent designed strictly for laboratory Stock Solution Preparation, available in multiple mass formats from 5mg to 120mg. It features a lyophilized “cake” of the Dual-Agonist Ligand (GLP/GIP-Tz), allowing researchers to reconstitute a single, uniform batch for longitudinal metabolic studies at the scale their protocol requires. Higher-mass formats eliminate inter-batch variance found in smaller units when large stock volumes are needed. Not for human use.